Recruiting

Observational Study

Sponsor:

Florida Atlantic University

Code:

NCT07127510

Conditions

Alzheimer Disease (AD)

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease.

Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.

Conditions

Alzheimer Disease (AD)

Study ID

NCT07127510

Start date

Mar 18, 2026

Status verified date

Mar, 2026

Completion date

Jun 1, 2027

Anticipated

Primary completion date

Apr 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
  • Age 65 to 80 included.
  • People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.

Exclusion Criteria:

  • Under the age of 65 or over the age of 80.
  • Advanced dementia such that the person would require sedation for undergoing an MRI scan.
  • Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
  • Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
  • Having a history of seizures.
  • Working at night.
  • Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
  • People with no AD: MoCA test result lower than 26.

Study Design

Enrollment

20 participants

Anticipated

Interventions and Outcome Measures

Arms

Alzheimer's disease group

People diagnosed with Alzheimer's disease

Control group

People without Alzheimer's disease

Primary outcome measure

  • Brain NAD [ Time Frame: At enrollment and 8 months after enrollment ]

Central Contacts and Locations

Central contacts

FAU Clinical Research Unit Central Contact

561-235-4467CRUDOR@health.fau.edu

Locations

FAU Clinical Research Unit

Recruiting

Boca Raton, Florida, United States, 33431

Contacts

Judyta Kociolek

5612974963CRUDOR@health.fau.edu

More Information

Sponsor

Florida Atlantic University

Last update posted

Mar 24, 2026

Last verified

Mar, 2026

Keywords

  • NAD
  • Alzheimer Disease (AD)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Florida Atlantic University on 2026-03-24.